|
|||||
|
|
Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients |
|
| Abstract: | |
| Keywords: | abiraterone acetate chemotherapy prognostic model metastatic castration‐resistant prostate cancer sequential treatment |